—sold primarily under the brand name Cipro, but also as Ciflox, Ciloxan, Baycip, Ciproxin, Prociflor, Ciprex, and Proquin—causes tendon breaks and Stevens-Johnson Syndrome. Cipro is the brand name for the drug in the early 1980s and introduced the drug in both Europe and the United States in 1987. The patent expired in 2003, allowing other pharmaceutical companies to create generic equivalents, which several did even though by then many bacteria strains had built up a resistance to . Bayer had found a winner in Cipro, selling $1.04 billion of the drug by 1999. Bayer also sold the federal government 100 million Cipro tablets during the 2001 anthrax scare; even at a reduced price, this still brought Bayer $204 per person treated over a 60-day period. Cipro is a broad-spectrum fluoroquinolone antibiotic, meaning that it can be used against many different bacteria strains. Broad-spectrum antibiotics effectively combat undetermined life-threatening bacterial infections (such as meningitis) and symptoms caused by multiple concurrent bacterial infections. The lawyers at Parker Waichman LLP are offering free consultations to individuals who experienced tendon ruptures and tendonitis after treatment with the antibiotic, Cipro (ciprofloxacin). If you or someone you know suffered a tendon injury as a result of taking Cipro, we urge you contact one of our Cipro injury lawyers risk free. Cipro is a member of the fluoroquinolone group of antibiotics prescribed to treat bacterial infections of the abdomen, bones, urinary tract, skin, and lower respiratory system. Health officials also prescribe Cipro to combat bronchial infections, typhoid fever, prostate gland infections, and tuberculosis. Cipro gained notoriety in 2001, when it was used to treat victims of anthrax attacks. As of 2011, more than 23 million patients were prescribed a fluoroquinolone by 2015. found that fluoroquinolone antibiotics are associated with an increased risk of aortic aneurysm and dissection.
Or emergency clinicians, the fluoroquinolone antibiotics have been a staple in combating both outpatient and inpatient infections. The first fluoroquinolone (ciprofloxacin/Cipro) came on the market in 1987, and since then there have been a raft of new quinolones added to the drug class. The fluoroquinolones have been shown to have a wide spectrum of biologic activity and are effective against a large number of bacteria pathogens. But post-marketing surveillance has demonstrated a growing number of serious and unexpected side effects. Perhaps the most commonly known unique side effect of the quinolones relate to their effect on connective tissue – particularly in the Achilles tendons. The relationship between tendon pathology and the quinolones was noted back in 1983, but the FDA was very reluctant to “Black Box” the drugs until a lawsuit filed by the non-profit “Public Citizen” pressured the FDA to acknowledge the problem. In the end the boxed warning took 25 years to appear, finally surfacing in 2008. The first lawsuit regarding tendon rupture occurred in 2010 when a Minnesota jury awarded $1.8 million to 82-year-old John Schedin who had bilateral achilles ruptures after being given levofloxacin for a respiratory infection along with some steroids by his family doctor. Bayer AG, the manufacturer of Cipro, is facing a growing number of product liability claims over the antibiotic’s alleged association with peripheral neuropathy and nerve damage. Cipro lawsuit plaintiffs accuse the company of concealing and downplaying this potential complication, and failing to provide adequate warnings to patients and doctors. The nationwide law firm of Bernstein Liebhard LLP is now offering free legal reviews to patients who were diagnosed with peripheral neuropathy that may be associated with their use of Cipro. Food & Drug Administration (FDA) is updating the boxed warning for Cipro and other systemic fluoroquinolones to state that the drugs are generally too dangerous for patients with sinusitis, bronchitis and uncomplicated urinary tract infections who have other treatment options. To learn more about the litigation involving this drug, please call (888) 994-5118. Their risks include issues affecting the tendons, muscles, joints, nerves and central nervous system that can occur together, and that may be permanent. Food & Drug Administration (FDA) ordered stronger warnings, after a review determined that the drugs’ labels did not adequately describe the rapid onset of the condition, or the potential for permanence. Read More Since 2004, the labels for Cipro and other fluoroquinolone antibiotics have included mention of peripheral neuropathy. The agency also required that language characterizing peripheral neuropathy as a rare occurrence be deleted. Peripheral neuropathy is nerve damage that causes injury to the nerves that carry messages between the brain, spinal cord, and body. Symptoms of this condition include: Plaintiffs who have filed Cipro lawsuits claim that they may have avoided this debilitating complication had Bayer AG provided doctors and patients with more accurate peripheral neuropathy warnings.
Lawsuits over fluoroquinolone antibiotics Cipro, Levaquin and Avelox say patients suffered aortic dissection or aortic aneurysm that required overnight hospitalization or surgery, or resulted in death, within one year of taking the prescription drugs. Jul 17, 2017. The first fluoroquinolone ciprofloxacin/Cipro came on the market in. a lawsuit filed by the non-profit “Public Citizen” pressured the FDA to.